Cellectis S.A.

Los Angeles, California

OncologyantibodyPhase IIListed · CLLS

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

3w agoTrial registeredJun 30, 2026Source filing (opens the source filing in a new tab)

Momentum

97no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Dec 31, 2026
Chronic Lymphocytic Leukemia · NOT_YET_RECRUITING · sponsor: M.D. Anderson Cancer Center · A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
ClinicalTrials.gov · NCT07674810 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 31, 2026
B-cell Acute Lymphoblastic Leukemia · NOT_YET_RECRUITING · sponsor: M.D. Anderson Cancer Center · Phase 1 Study Of KITE-753 in R/R B-Cell ALL
ClinicalTrials.gov · NCT07674823 (opens the source filing in a new tab)
Trial
PHASE2 registered
Dec 20, 2022
Leukemia · RECRUITING · sponsor: M.D. Anderson Cancer Center · Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
ClinicalTrials.gov · NCT05536349 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Oct 14, 2019
B-cell Acute Lymphoblastic Leukemia · RECRUITING · sponsor: Cellectis S.A. · Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
ClinicalTrials.gov · NCT04150497 (opens the source filing in a new tab)
Trial
NA registered
Mar 19, 2018
Rotator Cuff Tear · COMPLETED · sponsor: University of Michigan · Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears
ClinicalTrials.gov · NCT03295994 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 31, 2017
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
ClinicalTrials.gov · NCT02846623 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 7, 2016
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
ClinicalTrials.gov · NCT02756897 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 15, 2015
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia · TERMINATED · sponsor: M.D. Anderson Cancer Center · Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
ClinicalTrials.gov · NCT02420717 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 75%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
3w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Phase 1 Study Of KITE-753 in R/R B-Cell ALL
3w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears
3mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
5mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
5mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
10mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Jun 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE1/PHASE2 registered

NA registered

PHASE2 registered

PHASE2 registered

PHASE2 registered